Elevated serum alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality.

This study clarifies the molecular underpinnings of the GlycA biomarker's associated disease risk, and indicates a previously unrecognised association between elevated AAT and severe disease onset and mortality.